Relationship between plasma levels of soluble CD40L and insulin sensitivity and insulin secretion status in non-diabetic dyslipidemic patients

Diabetes Research and Clinical Practice

Volumn 79, Issue 1, 2008, Pages 48-55

  Filozof, Claudia ^a   Gómez Garre, Dulcenombre ^b   Reinares, Leonardo ^a   González Rubio, María Luisa ^b   Muñoz Pacheco, Paloma ^b   Rueda, Antonio ^a   Álvarez Arcaya, Arántzazu ^a   Calle Pascual, Alfonso L ^c   Fernández Cruz, Arturo ^a,b  

^a Cardiovascular Institute   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

CD40L; Dyslipidemic patients; Homeostasis model assessment (HOMA)

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; INSULIN; LIPID; PADGEM PROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CELL SURFACE; CONTROLLED STUDY; DIET RESTRICTION; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; FLOW CYTOMETRY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; BLOOD PLATELETS; BLOOD PRESSURE; BODY SIZE; BODY WEIGHT; CD40 LIGAND; DYSLIPIDEMIAS; FEMALE; FLOW CYTOMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED;

EID: 37549030477     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.07.002     Document Type: Article

References (39)

1. Ross R. Atherosclerosis. N. Engl. J. Med. 340 (1999) 115-126
2. Schönbeck U., and Libby P. CD40 signaling and plaque instability. Circ. Res. 89 (2001) 1092-1103
3. Inwald D.P., McDowall A., Peters M.J., Callard R.E., and Klein N.J. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ. Res. 92 (2003) 1041-1048
4. Schönbeck U., Sukhova G.K., Shimizu K., Mach F., and Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7458-7463
5. Bruemmer D., Riggers U., Holzmeister J., Grill M., Lippek F., Settmacher U., et al. Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions. Am. J. Cardiol. 87 (2001) 21-27
6. Semb A.G., van Wissen S., Ueland T., Smilde T., Waehre T., Tripp M.D., et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: down regulatory effect of statin therapy. J. Am. Coll. Cardiol. 41 (2003) 275-279
7. Cipollone F., Mezzetti A., Porreca E., Di Febbo C., Nutini M., Fazia M., et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia effects of statin therapy. Circulation 106 (2002) 399-402
8. Han S.H., Koh K.K., Quon M.J., Lee Y., and Shin E.K. The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Atherosclerosis 190 (2007) 205-211
9. Varo N., Vicent D., Libby P., Nuzzo R., Calle-Pascual A.L., Bernal M.R., et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients a novel target of thiazolidinediones. Circulation 107 (2003) 2664-2669
10. Aukrust P., Müller F., Ueland T., Berget T., Aaser E., Brunsvig A., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 (1999) 614-620
11. Varo N., de Lemos J.A., Libby P., Morrow D.A., Murphy S.A., Nuzzo R., et al. Soluble CD40L risk prediction after acute coronary syndromes. Circulation 108 (2003) 1049-1052
12. Schönbeck U., Varo N., Libby P., Buring J., and Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation 104 (2001) 2266-2268
13. Haffner S.M. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diab. Res. Clin. Pract. 6 (2003) S9-S18
14. Festa A., Hanley A.J.G., Tracy R.P., D'Agostino Jr. R., and Haffner S.M. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 108 (2003) 1822-1830
15. Temelkova-Kurktschiev T., Siegert G., Bergmann S., Henkel E., Koehler C., Jaross W., et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 51 (2002) 743-749
16. Hak A.E., Pols H.A.P., Stehouwer C.D.A., Meijer J., Kiliaan A.J., Hofman A., et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly the Rotterdam study. J. Clin. Endocrinol. Metab. 86 (2001) 4398-4405
17. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Targher G., et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck study. Diabetes 47 (1998) 1643-1649
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 285 (2001) 2486-2497.
19. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
20. Ascaso J.F., Romero P., Real J.T., Priego A., Valdecabres C., and Carmena R. Cuantificación de la insulinoresistencia con los valores de insulina basal e índice HOMA en una población no diabética. Med. Clín. Barcelona 117 (2001) 530-533
21. Hermans M.P., Levy J.C., Morris R.J., and Turner R.C. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 42 (1999) 678-687
22. Hermans M.P., Levy J.C., Morris R.J., and Turner R.C. Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Diabetes 48 (1999) 1779-1786
23. Haffner S., Miettinen H., and Stern M.P. The homeostasis model in the San Antonio Heart Study. Diab. Care 20 (1997) 1087-1092
24. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diab. Care 23 (2000) 57-63
25. Desideri G., and Ferri C. Effects of obesity and weight loss on soluble CD40L levels. JAMA 289 (2003) 1781-1782
26. Marx N., Imhof A., Froehlich J., Siam L., Ittner J., Wierse G., et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107 (2003) 1954-1957
27. Zhu S., Wang Z., Heshka S., Heo M., Faith M.S., and Heymsfield S.B. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey clinical action thresholds. Am. J. Clin. Nutr. 76 (2002) 743-749
28. Schernthaner G.H., Kopp H.P., Krzyzanowska K., Kriwanek S., Koppensteiner R., and Schernthaner G. Soluble CD40L in patients with morbid obesity significant reduction after bariatric surgery. Eur. J. Clin. Invest. 36 (2006) 395-401
29. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., and Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diab. Care 22 (1999) 920-924
30. Novoa F.J., Boronat M., Saavedra P., Díaz-Cremades J.M., Varillas V.F., La Roche F., et al. Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation. Diab. Care 28 (2005) 2388-2393
31. Furman M.I., Krueger L.A., Linden M.D., Barnard M.R., Frelinger A.L., and Michelson A.D. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerisation. JACC 43 (2004) 2319-2325
32. Labiós M., Martínez M., Gabriel F., Guiral V., Martínez E., and Aznar J. Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry. Thromb. Res. 115 (2005) 263-270
33. Hermann A., Rauch B.H., Braun M., Schror K., and Weber A.A. Platelet CD40 ligand (CD40L)-subcellular localisation, regulation of expression, and inhibition by clopidogrel. Platelets 12 (2001) 74-82
34. André P., Nannizzi-Alaimo L., Prasad S.K., and Phillips D.R. Platelet derived CD40L. The switch-hitting player of cardiovascular disease. Circulation 103 (2002) 896-899
35. Verma S., Li S.H., Wang C.H., Fedak P.W., Li R.K., Weisel R.D., et al. Resistin promotes endothelial cell activation further evidence of adipokine-endothelial interaction. Circulation 108 (2003) 736-740
36. Ishizaka N., Ishizaka Y., Takahashi E., Unuma T., Tooda E., Nagai R., et al. Association between insulin resistance and carotid arteriosclerosis in subjects with normal fasting glucose and normal glucose tolerance. Arterioscler Thromb. Vasc. Biol. 23 (2003) 295-301
37. Bonora E., Kiechil S., Willeit J., Oberhollenzer F., Egger G., Meigs J.B., et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population. Diab. Care 30 (2007) 318-324
38. Forst T., Hohberg C., Fuellert S.D., Lubben G., Konrad T., Lobig M., et al. Pharmacological PPARγ stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm. Metab. Res. 37 (2005) 521-527
39. Akbiyik F., Ray D.M., Gettings K.F., Blumberg N., Francis C.W., and Phipps R.P. Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 104 (2004) 1361-1368